SCHEDULE: RA Capital Management Adjusts Werewolf Therapeutics Stake

RA Capital Management and affiliated entities have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Werewolf Therapeutics, Inc. common stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed Amendment No. 12 to their Schedule 13D regarding their beneficial ownership of Werewolf Therapeutics, Inc. common stock.
• The filing indicates a decrease in beneficial ownership, with the Reporting Persons ceasing to be beneficial owners of more than five percent of the common stock on June 30, 2026.
• As of the filing date, RA Capital Management, L.P. beneficially owns 1,985,541 shares, representing 4.1% of the class. Peter Kolchinsky and Rajeev Shah also hold 1,985,541 shares (4.1%). RA Capital Healthcare Fund, L.P. beneficially owns 1,853,646 shares, representing 3.8%.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as slightly negative due to the reduction in stake by a significant investor, indicating a potential decrease in confidence or a strategic reallocation of capital.

Negatives

• The Reporting Persons have reduced their stake in Werewolf Therapeutics, Inc., ceasing to be beneficial owners of more than five percent of the common stock as of June 30, 2026.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It primarily details changes in beneficial ownership by RA Capital Management and its affiliates.

Industry Context

StockSavvy.ai notes that this filing reflects a common activity for investment management firms, particularly those focused on the healthcare and biotechnology sectors, where significant portfolio adjustments can occur based on market conditions and investment strategies. The reduction in stake by a major holder like RA Capital Management may signal a shift in their investment thesis or a realization of gains.

Stakeholder Impact

• Shareholders may view the reduction in stake by RA Capital Management as a potential negative signal, possibly impacting share price in the short term.
• The market may interpret this as a sign of RA Capital's evolving investment strategy or a realization of profits.

Key Dates

Recommendation

The filing primarily reports a reduction in beneficial ownership by RA Capital Management, which is a significant event. However, without further context on the company's performance or strategic direction, a 'hold' recommendation is prudent, allowing investors to observe the market's reaction and await further company disclosures.

Keywords

Schedule 13D, RA Capital Management, Werewolf Therapeutics, Beneficial Ownership, Stock Sale, SEC Filing, Investment Fund